Stockscreener 앱 받기
0.00
100.00%
-22.93
Landos Biopharma Inc 주식(LABP)의 최신 뉴스
Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates - Marketscreener.com
AbbVie inks immune disorder drug licensing deal with China's FutureGen - Reuters
AbbVie concludes acquisition of Landos Biopharma - Medical Dialogues
(LABP) Trading Report - Stock Traders Daily
Landos Biopharma (NASDAQ:LABP) Stock Price Up 0.6% - MarketBeat
Landos Biopharma (NASDAQ:LABP) Trading Up 0.6% - Defense World
AbbVie finalizes Landos Biopharma acquisition - Investing.com India
AbbVie finalizes Landos Biopharma acquisition By Investing.com - Investing.com
AbbVie finalizes Landos Biopharma acquisition By Investing.com - Investing.com UK
AbbVie Completes Acquisition of Landos Biopharma - PR Newswire
When the Price of (LABP) Talks, People Listen - Stock Traders Daily
LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC ... - Business Wire
LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC ... - Barron's
Landos Biopharma's Latest Deal Faces Tough Regulatory Gauntlet: HSR Act and FTC Scrutiny May Impose Delays ... - TipRanks
5 Biotech Stocks Set to Outpace Q1 Earnings Estimates - Yahoo Movies UK
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit OutlookAbbVie (NYSE ... - Benzinga
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards? - Zacks Investment Research
Stockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVie - Morningstar
AbbVie to Acquire Landos Biopharma and Novel Ulcerative Colitis Investigational Drug - Managed Healthcare Executive
This Biopharma Stock Outperformed MSTR and SMCI in March 2024TipRanks.com - TipRanks
ZUU Co. Ltd. executives purchase Pono Capital two shares worth $390 By Investing.com - Investing.com
Opinion: AbbVie-Landos Deal Signals Continued Momentum for Next-Gen I&I Drugs - BioSpace
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio - Zacks Investment Research
AbbVie to acquire Landos Biopharma for $20.42 per share in cash plus CVRTipRanks.com - TipRanks
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio - Yahoo Finance
Nasdaq Turns Higher; Akanda Shares Plunge - Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Benzinga
Crude Oil Moves Higher; US New Home Sales Fall In February - Benzinga
US Stocks Down; Chicago Fed National Activity Index Rises In February - Benzinga
Landos Biopharma’s Definitive Merger with AbbVie Subsidiary - TipRanks
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases - GlobeNewswire Inc.
AbbVie to buy Landos Biopharma for $212M - USA Herald
Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely? - Simply Wall St
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results - GlobeNewswire Inc.
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results - Yahoo Finance
Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely? - Yahoo Finance
Landos’s NX-13 shows symptom relief in Phase Ib ulcerative colitis trial - Clinical Trials Arena
Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn's and Colitis - Yahoo Finance
Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results - Yahoo Finance
Ulcerative Colitis Market to Grow Positively by 2032, - GlobeNewswire
Scientists behind LANCL2 target launch with phase III-ready drug - BioWorld Online
Landos Biopharma Appoints Alka Batycky to Board - citybiz
Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D. - Yahoo Finance
Landos Biopharma Announces 1-for-10 Reverse Stock Split - Yahoo Finance
UPDATE -- Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results - GlobeNewswire
BRIEF—New biotech NImmune Biopharma buys assets from Landos | Pharmaceutical | The Pharmaletter - The Pharma Letter
Josep Bassaganya-Riera Launches NImmune Biopharma with Phase 3-Ready Clinical Candidate Omilancor for the Treatment of Ulcerative Colitis and Crohn’s Disease - Business Wire
Blacksburg biotech firm facing headwinds - Roanoke Times
Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual ... - GlobeNewswire
Landos Biopharma Provides Comprehensive Update on Clinical Development Plans - StockTitan
3 Top Biotech Penny Stocks Under $3 To Watch Right Now - Penny Stocks
Landos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical Officer - GlobeNewswire
Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial - GlobeNewswire
Landos Names Gregory Oakes President and Chief Executive Officer - GlobeNewswire
Landos Biopharma Appoints Roger Adsett to its Board of Directors - Yahoo Canada Finance
Swvl Hldgs Stock (NASDAQ:SWVL), Quotes and News Summary - Benzinga
Sonder Holdings Stock (NASDAQ:SOND), Quotes and News Summary - Benzinga
Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update - citybiz
Landos Biopharma gets dosing underway in early-stage LABP-104 lupus study - Seeking Alpha
Landos Biopharma’s Phase 2 Data of Omilancor in Ulcerative - GlobeNewswire
Vimeo Stock (NASDAQ:VMEO), Quotes and News Summary - Benzinga
Lianbio licenses Landos’ LANCL2- and NLRX1-targeted candidates in $218M deal for UC and CD - BioWorld Online
Perceptive Advisors Joins Biotech Investment Boom With $515M Fund - Business Insider
Bausch Health and Landos Biopharma See Activist Action - Barron's
LABP Stock Price and Chart — NASDAQ:LABP - TradingView
LABP IPO NewsAutoimmune biotech Landos Biopharma prices IPO at $16 midpoint - Renaissance Capital
Landos Biopharma Announces Pricing of Initial Public Offering - GlobeNewswire
LABP IPO NewsAutoimmune biotech Landos Biopharma sets terms for $100 million IPO - Renaissance Capital
Brainstorm Cell Stock (NASDAQ:BCLI), Quotes and News Summary - Benzinga
LABP IPO NewsAutoimmune biotech Landos Biopharma files for a $100 million IPO - Renaissance Capital
XTL Biopharmaceuticals Stock (NASDAQ:XTLB), Quotes and News Summary - Benzinga
UroGen Pharma Stock (NASDAQ:URGN), Quotes and News Summary - Benzinga
Target Hospitality Stock (NASDAQ:TH), Quotes and News Summary - Benzinga
Landos Biopharma Announces First Human Dosing in a Phase 1 Study of NX-13, its Novel Candidate for Inflammatory ... - GlobeNewswire
Landos Biopharma Announces First Patient Dosed in Global Phase 2 Clinical Trial of BT-11 in Mild to Moderate ... - Business Wire
Landos Biopharma Completes $60 Million Series B Financing - Business Wire
Landos Biopharma Announces Publication of Results from Non-clinical Toxicity Studies Further Characterizing the Safety Profile of BT-11 - Business Wire
1.19%
1.65%
자본화:
|
볼륨(24시간):